Does the evidence support population-wide screening for type 2 diabetes? No
- PMID: 28831520
- DOI: 10.1007/s00125-017-4393-1
Does the evidence support population-wide screening for type 2 diabetes? No
Abstract
Large-scale, centrally-coordinated screening for undiagnosed type 2 diabetes is an attractive option to reduce the mortality and morbidity resulting from inadequately controlled diabetes. However, there is limited research examining the direct consequences of such screening programmes on outcomes such as cardiovascular disease and death. Two papers published in this edition of Diabetologia (DOIs: 10.1007/s00125-017-4323-2 and 10.1007/s00125-017-4299-y ) examine data from one of the very few trials conducted in this area. Overall, there was little benefit that could be directly related to the screening programme. In part, this was due to the high levels of opportunistic screening in the control group. Thus, when there are high levels of opportunistic screening for type 2 diabetes, there remains no clear evidence of benefit of centrally-coordinated screening programmes that approach individuals outside usual healthcare settings.
Keywords: Cardiovascular disease; Mortality; Screening; Type 2 diabetes.
Comment on
-
Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults.Diabetologia. 2017 Nov;60(11):2183-2191. doi: 10.1007/s00125-017-4323-2. Epub 2017 Aug 23. Diabetologia. 2017. PMID: 28831535 Free PMC article. Clinical Trial.
-
Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009.Diabetologia. 2017 Nov;60(11):2192-2199. doi: 10.1007/s00125-017-4299-y. Epub 2017 Aug 23. Diabetologia. 2017. PMID: 28831539 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical